

66th American Society of Hematology Annual Meeting and Exposition
December 7-10, 2024
San Diego, California
Abstracts¹

Have been published in Blood; links provided

CCTG ALC.2/ CALGB 10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML).

Time: Saturday, December 7, 2024: 2:15 PM

Location: Halls G-H (San Diego Convention Centre)

Type: Oral

Session: 617 – Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML Hematology Disease Topics & Pathways

Abstract: ***10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years***

Authors: Richard M Stone, Jun Yin, Sumithra J Mandrekar, Axel Benner, Maral Saadati, Ilene A. Galinsky, Ben L. Sanford, Rebecca Teske, Susan M. Geyer, Thomas Prior, Sergio Amadori, Frederick R. Appelbaum, Joseph Brandwein, Konstanze Döhner, Gerhard Ehninger, Arnold Ganser, Rebecca B. Klisovic, Jürgen Krauter, Guido Marcucci, Bruno Medeiros, Dietger W. Niederwieser, Miguel A. Sanz, Richard F. Schlenk, Hubert Serve, Jorge Sierra, Martin S. Tallman, Andrew H Wei, Theo J.M. de Witte, Christian Thiede, Hartmut Döhner, Richard A. Larson

Link: <https://ash.confex.com/ash/2024/webprogram/Paper201058.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/218/530722/10-Year-Follow-up-of-CALGB-10603-Ratify?searchresult=1>

CCTG ALC.6/ ALLIANCE A041501: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/ Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia

Time: Saturday, December 7, 2024: 4:15 PM

Location: Halls G-H (San Diego Convention Centre)

Type: Oral

Session: 613 – Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients

Abstract: ***308 Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial***

Authors: Daniel J. DeAngelo, Jun Yin, Anjali S. Advani, Selina Luger, Jill Fulcher, Michaela Liedtke, Geoffrey L. Uy, Shira N. Dinner, Lindsay Wilde, Marlise R. Luskin, Caner Saygin, Ella Postich, Noreen Fulton, Richard C. Harvey, Gaby E Perez Burbano, Rebecca Teske, Harry P. Erba, Mark R. Litzow, Richard M. Stone, Wendy Stock

Link: <https://ash.confex.com/ash/2024/webprogram/Paper209438.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/308/530921/Addition-of-Inotuzumab-to-a-Pediatric-Inspired>

¹ A searchable directory of abstracts is available using this link ... <https://ash.confex.com/ash/2023/webprogram/start.html>.

CCTG ALC.1/ SWOG: A Phase III Study Of The Addition Of Mylotarg® During Induction Therapy Verses Standard Induction With Daunomycin & Cytosine Arabinoside Followed By Consolidation & Subsequent Randomization To Post-Consolidation Therapy With Mylotarg® Or No Additional Therapy For Patients Under The Age Of 61 With Previously Untreated De Novo Acute Myeloid Leukemia

Time: Saturday, December 7, 2024: 5:30-730 PM

Location: Halls G-H (San Diego Convention Centre)

Type: Poster

Session: 619 – Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I

Abstract: ***1568 Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases***

Authors: Adam Sciambi, Daniel Mendoza, Kathryn Thompson, Lan W. Beppu, Benjamin Geller, Indira Krishnan, Lubna Nousheen, Shu Wang, Charlie Murphy, Jerald P. Radich, Todd E. Druley

Link: <https://ash.confex.com/ash/2024/webprogram/Paper210840.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/1568/529268/Single-Cell-Multi-Omic-Analysis-of-AML-MRD-Reveals>

CCTG ALC.1/ SWOG 0106: A Phase III Study Of The Addition Of Mylotarg® During Induction Therapy Verses Standard Induction With Daunomycin & Cytosine Arabinoside Followed By Consolidation & Subsequent Randomization To Post-Consolidation Therapy With Mylotarg® Or No Additional Therapy For Patients Under The Age Of 61 With Previously Untreated De Novo Acute Myeloid Leukemia

Time: Monday, December , 2024: 6:00-8:00 PM

Location: Halls G-H (San Diego Convention Centre)

Type: Poster

Session: 618 – Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III Hematology Disease Topics & Pathways

Abstract: ***4309 Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG***

Authors: Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogossova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Link: <https://ash.confex.com/ash/2024/webprogram/Paper198506.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/4309/533807/Evaluation-of-ELN2022-Risk-Stratification-in-NPM1?searchresult=1>

CCTG ALC.4/ ECOG-ACRIN E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

Time: Monday, December 9, 2024: 6:00-8:00PM

Location: Halls G-H (San Diego Convention Centre)

Type: Poster

Session: 613 – Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research

Abstract: ***4211 Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR:ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial***

Authors: Nikolai A. Podoltsev, Zhuoxin Sun, Mark R. Litzow, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit

Vachhani, Rupali Roy, Elad Sharon, Richard F. Little, Harry Erba, Richard M. Stone, Charles G. Mullighan, Martin S. Tallman, Selina Luger, Ryan J Mattison

Link: <https://ash.confex.com/ash/2024/webprogram/Paper207143.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/4211/532414/Addition-of-Blinatumomab-to-Consolidation-Therapy?searchresult=14211>

CCTG ALC.4/ ECOG-ACRIN E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

Time: Monday, December 9, 2024: 11:30am

Location: Halls G-H (San Diego Convention Centre)

Type: Oral

Session: 732 – Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, ALL, Bispecific Antibody Therapy, Clinical Research, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Measurable Residual Disease , Transplantation (Allogeneic and Autologous)

Abstract: ***779 Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial***

Authors: Michaela Liedtke, Zhuoxin Sun, Mark R. Litzow, Ryan J Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M. Stone, Selina Luger, MD, Charles G. Mullighan, Martin S. Tallman, Matthew J. Wieduwilt

Link: <https://ash.confex.com/ash/2024/webprogram/Paper207557.html>

Citation: <https://ashpublications.org/blood/article/144/Supplement%201/779/530965/Assessment-of-Outcomes-of-Allogeneic-Stem-Cell?searchresult=1>
